Judah Frommer Analyst PerformanceSenior Equity Research Analyst, SMid Cap Biotech at Morgan StanleyJudah Frommer is a stock analyst at Morgan Stanley focused in the healthcare sector, covering 31 publicly traded companies. Over the past year, Judah Frommer has issued 36 stock ratings, including buy, hold, and sell recommendations. While full access to Judah Frommer's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Judah Frommer's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings96 Last 8 YearsBuy Recommendations67.37% 64 Buy RatingsCompanies Covered31 Unique Companies Ratings Distribution95RatingsDistribution of strong buy, buy, hold, and sell ratings by Judah Frommer.RatingPercentageCount Strong Buy0.0%0 ratings Buy67.4%64 ratings Hold29.5%27 ratings Sell3.2%3 ratingsOut of 95 total stock ratings issued by Judah Frommer at Morgan Stanley, the majority (67.4%) have been Buy recommendations, followed by 29.5% Hold and 3.2% Sell.Best & Worst CallsBest Call000.0%CLDXMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ATAINov 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ80.6% of companies on NASDAQ25 companiesNYSE19.4% of companies on NYSE6 companiesJudah Frommer, an analyst at Morgan Stanley, currently covers 31 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare22 companies71.0%Consumer Staples7 companies22.6%Consumer Discretionary2 companies6.5%Judah Frommer of Morgan Stanley specializes in stock coverage within the Healthcare sector, with additional focus on Consumer Staples and Consumer Discretionary companies.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY17 companies54.8%CONSUMER STAPLES DISTRIBUTION & RETAIL7 companies22.6%PHARMACEUTICALS5 companies16.1%BROADLINE RETAIL1 company3.2%SPECIALTY RETAIL1 company3.2% Judah Frommer's Ratings History at Morgan Stanley Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsTRVITrevi Therapeutics8/7/2026Reiterated Rating$18.28$23.00Overweight$0.0000.00% ROICLDXCelldex Therapeutics8/7/2026Boost Price Target$41.69$46.00Overweight$0.0000.00% ROIKYMRKymera Therapeutics8/6/2026Reiterated Rating$104.78$135.00Overweight$0.0000.00% ROICMPSCompass Pathways8/6/2026Boost Price Target$13.53$18.00Overweight$0.0000.00% ROIPTCTPTC Therapeutics7/31/2026Boost Price Target$75.52$104.00Overweight$0.0000.00% ROIINCYIncyte7/29/2026Set Price Target$128.66$119.00$0.0000.00% ROIABVXAbivax7/24/2026Reiterated Rating$129.24$180.00Overweight$0.0000.00% ROIINCYIncyte7/23/2026Boost Price Target$117.50$104.00Equal Weight$0.0000.00% ROICLDXCelldex Therapeutics7/22/2026Lower Price Target$34.31$40.00Overweight$0.0000.00% ROICMPSCompass Pathways7/7/2026Reiterated Rating$12.89$17.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. EVMNEvommune6/30/2026Lower Price Target$15.08$26.00Overweight$0.0000.00% ROIENGNenGene6/18/2026Downgrade$1.74$3.00Underweight$0.0000.00% ROIABVXAbivax6/2/2026Lower Price Target$129.69$132.00Overweight$0.0000.00% ROIAVLNAvalyn Pharma5/26/2026Initiated Coverage$28.84$53.00Overweight$0.0000.00% ROIZBIOZenas BioPharma5/14/2026Boost Price Target$19.11$22.00Equal Weight$0.0000.00% ROIBCAXBicara Therapeutics5/12/2026Boost Price Target$22.57$37.00Overweight$0.0000.00% ROIEVMNEvommune5/11/2026Boost Price Target$24.54$55.00Overweight$0.0000.00% ROITRVITrevi Therapeutics5/6/2026Reiterated Rating$14.66$20.00Overweight$0.0000.00% ROIKLRSKalaris Therapeutics4/16/2026Initiated Coverage$5.87$14.00Overweight$0.0000.00% ROIIMMXImmix Biopharma3/25/2026Initiated Coverage$8.57$20.00Overweight$0.0000.00% ROITRVITrevi Therapeutics3/18/2026Lower Price Target$10.80$18.00Overweight$0.0000.00% ROIZBIOZenas BioPharma3/17/2026Boost Price Target$23.23$21.00Equal Weight$0.0000.00% ROIRGNXREGENXBIO3/5/2026Lower Price Target$8.72$17.00Overweight$0.0000.00% ROIAGMBAgomAb Therapeutics3/3/2026Initiated Coverage$16.21$28.00Overweight$0.0000.00% ROIBLTEBelite Bio3/3/2026Boost Price Target$173.12$201.00Overweight$0.0000.00% ROIEVMNEvommune2/18/2026Reiterated Rating$31.12$54.00Overweight$0.0000.00% ROIGMABGenmab A/S2/16/2026Initiated Coverage$30.03$34.00Equal Weight$0.0000.00% ROIRGNXREGENXBIO2/10/2026Lower Price Target$8.92$18.00Overweight$0.0000.00% ROIABVXAbivax1/9/2026Boost Price Target$115.49$145.00Overweight$0.0000.00% ROIBLTEBelite Bio1/6/2026Initiated Coverage$159.42$191.00Overweight$0.0000.00% ROIZBIOZenas BioPharma1/5/2026Downgrade$13.62$19.00Equal Weight$0.0000.00% ROIEVMNEvommune12/1/2025Initiated Coverage$20.71$36.00Overweight$0.0000.00% ROITRVITrevi Therapeutics11/14/2025Boost Price Target$11.46$19.00Overweight$0.0000.00% ROIZBIOZenas BioPharma11/13/2025Boost Price Target$35.80$37.00Overweight$0.0000.00% ROIABVXAbivax9/12/2025Boost Price Target$83.12$101.00Overweight$0.0000.00% ROITRVITrevi Therapeutics8/21/2025Initiated Coverage$7.42$18.00Overweight$0.0000.00% ROIAPLSApellis Pharmaceuticals7/2/2025Boost Price Target$18.25$26.00Equal Weight$0.0000.00% ROICLDXCelldex Therapeutics5/9/2025Lower Price Target$18.79$43.00Overweight$00.0000.00% ROICLDXCelldex Therapeutics3/20/2025Initiated Coverage$19.95$46.00Overweight$00.0000.00% ROIABVXAbivax3/20/2025Reiterated Rating$6.84$12.00Equal Weight$000.0000.00% ROIThe end may be near for these iconic stocks (Ad)Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.Watch Marc Chaikin's free presentation and get his full buy-and-sell list todayRGNXREGENXBIO3/14/2025Boost Price Target$6.55$24.00Overweight$0.0000.00% ROILKFTLakefront Biotherapeutics American Depositary Shares2/14/2025Downgrade$25.49$22.00Underweight$00.0000.00% ROIFDMT4D Molecular Therapeutics1/13/2025Lower Price Target$4.80$6.00Underweight$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
